QUOTE AND NEWS
Benzinga  May 7  Comment 
Morgan Stanley says in a recent report that it raises its price target on Overweight-rated Valeant Pharmaceuticals (NYSE: VRX) from $57 to $61. Morgan Stanley comments, "We raise our 2012-2015e EPS by 5-10% and bump our PT from $57 to $61 on...
Benzinga  May 7  Comment 
Below are the top drug delivery stocks on the NYSE and the NASDAQ in terms of operating margin. The trailing-twelve-month operating margin at Valeant Pharmaceuticals International Inc (NYSE: VRX) is 24.98%. VRX's revenue for the same period is...
PR Newswire  May 4  Comment 
VANCOUVER, British Columbia, May 4, 2012 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Green Mountain Coffee (NASDAQ:GMCR), JPMorgan (NYSE:JPM), Valeant (NYSE:VRX), AT&T
The Globe and Mail  May 3  Comment 
Drug company acquires skincare products from University Medical Pharmaceuticals in latest purchase
StreetInsider.com  May 3  Comment 
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today. 52-Week High: Valeant Pharmaceuticals (NYSE: VRX) high of $59.99. The pharma reported first-quarter EPS of 99 cents, from 2...
The Globe and Mail  May 3  Comment 
Pharmaceutical giant bolsters over-the-counter section
Reuters  May 3  Comment 
Valeant Pharmaceuticals International Inc posted a bigger-than-expected adjusted quarterly profit and raised its forecast for the year as acquisitions boost sales, sending its...
Reuters  May 3  Comment 
Canada's Valeant Pharmaceuticals International Inc reported a quarterly loss hurt in part by higher costs.
PR Newswire  May 3  Comment 
MONTREAL, May 3, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Valeant has agreed to acquire certain assets from University Medical Pharmaceuticals Corp., a specialty pharmaceutical
StreetInsider.com  May 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Valeant+Pharmaceuticals+%28VRX%29+Posts+Q1+EPS+of+99c%3B+Boosts+FY12+Outlook/7398432.html for the full story.





You may also be interested in articles related to Valeant Pharmaceuticals International (VRX):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki